joseph_jimenez

Novartis CEO Jimenez announces retirement in 2018

pharmafile | September 4, 2017 | News story | Sales and Marketing Novartis, Vasant Narasimhan, joe jimenez, pharma, pharmaceuticals 

Novartis has announced that its Chief Executive, Joe Jimenez (pictured), is set to retire next year. In his place, Vasant Narasimhan, its Global Head of Drug Development and Chief Medical Officer, will step up to lead the company.

Jimenez, 58, has held the top position since 2010 and has been with the company for a decade. He will step down from the role on 31 January, 2018, and will continue to operate in an advisory capacity until he retires fully from Novartis on 31 August. During his time with Novartis, he was responsible for restructuring the company after a period of rapid global expansion.

“During his tenure, Joe focused Novartis on leading global businesses, while divesting non-core divisions,” commented Chairman Joerg Reinhardt. “Under his leadership the innovation pipeline was rejuvenated, and we successfully navigated the patent expirations of our two largest products.”

Jimenez himself remarked “Both from a professional and a personal perspective, this is the right moment to hand the leadership reins of the company to Vas. Our strong pipeline and the strategic moves we have taken to focus the company have put Novartis on a strong path for the future.”

“On the personal side, after 10 wonderful years in Switzerland, my family is ready to return to Silicon Valley and the US,” he added.

Reinhardt also praised Jimenez’s replacement: “Vas is deeply anchored in medical science, has significant experience in managing the interfaces between research and development and commercial units and has strong business acumen with a track record of outstanding achievements.”

Matt Fellows

Related Content

Novartis shares new data about Fabhalta for IgAN treatment

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …

chuttersnap-oijvdm3zx4i-unsplash

Novartis shares new data for Zolgensma in children with SMA

Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …

Novartis to acquire MorphoSys AG for €2.7bn

Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, …

Latest content